ArticleFrontiers in immunology2026
A four-dimensional spatial atlas of spinal cord injury reveals predominant Spp1-integrin signaling driving microglia-fibroblast crosstalk in fibrotic niches.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spinal cord injury (SCI) leads to fibrotic scarring that blocks axonal regeneration, yet the molecular mechanisms controlling scar formation remain incompletely understood. Microglia and fibroblasts accumulate at lesion sites, but their intercellular communication, spatial organization and therapeutic tractability have not been systematically mapped. Methods: We integrated spatial transcriptomics, single-cell transcriptomics, bulk RNA sequencing, and microarray profiling across multiple post-injury time points in mouse and rat SCI models. A four-dimensional spatial atlas spanning three spatial dimensions and time was constructed to map microglia-fibroblast interactions. Fibroblast differentiation trajectories were used to establish molecular subtypes and a risk prediction model, validated in independent cohorts and human peripheral blood. NT3-chitosan was tested in a complete transection model with functional and molecular assessments. Results: The four-dimensional spatial atlas identified Spp1-Itgav/Itgb1 as the dominant microglia-to-fibroblast signaling axis during peak scar consolidation, spatially colocalized with NF-κB and TGF-β transcriptional programs. Fibroblast differentiation-based classification stratified SCI into three subtypes associated with injury severity and immune remodeling. A risk model based on fibroblast differentiation-associated signatures in peripheral blood predicted ASIA grade A with AUCs of 0.883, 0.939, and 0.807 in the total, training, and test sets, respectively. NT3-chitosan treatment was associated with reduced Spp1-Itgav/Itgb1 signaling, diminished fibrotic scarring, and sustained locomotor recovery over 52 weeks. Conclusion: Microglia-fibroblast crosstalk via Spp1-Itgav/Itgb1 is enriched in regions of fibrotic scar maturation, alongside NF-κB and TGF-β transcriptional activation. The fibroblast differentiation-based framework enables risk stratification and guides scar-targeted interventions, providing a clinically actionable pathway for SCI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.